(MANH) Manhattan Associates - Overview
Stock: Warehouse, Transportation, Omni-Channel, Inventory, Platform
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 44.4% |
| Relative Tail Risk | -10.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.70 |
| Alpha | -46.86 |
| Character TTM | |
|---|---|
| Beta | 1.303 |
| Beta Downside | 1.160 |
| Drawdowns 3y | |
|---|---|
| Max DD | 56.21% |
| CAGR/Max DD | 0.01 |
Description: MANH Manhattan Associates January 06, 2026
Manhattan Associates (NASDAQ: MANH) builds and services cloud-native software that digitizes supply-chain, warehouse, transportation and omni-channel operations for a broad set of industries-including retail, consumer goods, food & grocery, logistics providers, and life sciences. Its product suite spans Manhattan Active Warehouse Management, Manhattan SCALE logistics execution, Manhattan Active Omni (order-to-cash), inventory-optimization tools, and a platform-as-a-service foundation that supports on-premise and subscription deployments. The company sells primarily through a direct sales force and channel partners, and it also resells hardware such as RFID readers and barcode scanners.
Key data points (FY 2023): revenue of $1.23 billion, up ~10% YoY, with subscription-based ARR now representing roughly 70% of total revenue and gross margins expanding to 44% as cloud adoption accelerates. The business benefits from macro trends like e-commerce penetration (global e-commerce sales grew ~15% YoY) and persistent labor shortages in warehousing, which drive demand for automation and SaaS logistics solutions. However, competition from SAP, Oracle and niche TMS providers, plus exposure to retail cyclicality, remain material risk factors.
For a deeper quantitative view of MANH’s valuation and risk profile, you might find ValueRay’s analyst toolkit worth a look.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 219.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.40 > 0.02 and ΔFCF/TA 3.90 > 1.0 |
| NWC/Revenue: 11.78% < 20% (prev 9.88%; Δ 1.91% < -1%) |
| CFO/TA 0.41 > 3% & CFO 347.1m > Net Income 219.9m |
| Net Debt (-216.4m) to EBITDA (292.2m): -0.74 < 3 |
| Current Ratio: 1.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.6m) vs 12m ago -2.20% < -2% |
| Gross Margin: 55.74% > 18% (prev 0.54%; Δ 5519 % > 0.5%) |
| Asset Turnover: 135.4% > 50% (prev 137.6%; Δ -2.16% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z'' 5.37
| A: 0.15 (Total Current Assets 583.3m - Total Current Liabilities 455.9m) / Total Assets 839.4m |
| B: 0.41 (Retained Earnings 345.1m / Total Assets 839.4m) |
| C: 0.36 (EBIT TTM 285.9m / Avg Total Assets 798.5m) |
| D: 0.60 (Book Value of Equity 314.8m / Total Liabilities 524.6m) |
| Altman-Z'' Score: 5.37 = AAA |
Beneish M -3.28
| DSRI: 0.98 (Receivables 214.7m/210.7m, Revenue 1.08b/1.04b) |
| GMI: 0.97 (GM 55.74% / 54.21%) |
| AQI: 0.86 (AQ_t 0.22 / AQ_t-1 0.25) |
| SGI: 1.04 (Revenue 1.08b / 1.04b) |
| TATA: -0.15 (NI 219.9m - CFO 347.1m) / TA 839.4m) |
| Beneish M-Score: -3.28 (Cap -4..+1) = AA |
What is the price of MANH shares?
Over the past week, the price has changed by -3.93%, over one month by -14.06%, over three months by -17.33% and over the past year by -26.76%.
Is MANH a buy, sell or hold?
- StrongBuy: 5
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MANH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 217.3 | 49.8% |
| Analysts Target Price | 217.3 | 49.8% |
| ValueRay Target Price | 133.2 | -8.2% |
MANH Fundamental Data Overview February 04, 2026
P/E Forward = 28.9017
P/S = 8.3969
P/B = 28.7111
P/EG = 1.8307
Revenue TTM = 1.08b USD
EBIT TTM = 285.9m USD
EBITDA TTM = 292.2m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 112.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -216.4m USD (from netDebt column, last quarter)
Enterprise Value = 8.86b USD (9.08b + Debt 112.4m - CCE 328.7m)
Interest Coverage Ratio = unknown (Ebit TTM 285.9m / Interest Expense TTM 0.0)
EV/FCF = 26.60x (Enterprise Value 8.86b / FCF TTM 333.2m)
FCF Yield = 3.76% (FCF TTM 333.2m / Enterprise Value 8.86b)
FCF Margin = 30.81% (FCF TTM 333.2m / Revenue TTM 1.08b)
Net Margin = 20.34% (Net Income TTM 219.9m / Revenue TTM 1.08b)
Gross Margin = 55.74% ((Revenue TTM 1.08b - Cost of Revenue TTM 478.7m) / Revenue TTM)
Gross Margin QoQ = 54.41% (prev 55.96%)
Tobins Q-Ratio = 10.56 (Enterprise Value 8.86b / Total Assets 839.4m)
Interest Expense / Debt = 0.59% (Interest Expense 667.0k / Debt 112.4m)
Taxrate = 24.10% (16.5m / 68.5m)
NOPAT = 217.0m (EBIT 285.9m * (1 - 24.10%))
Current Ratio = 1.28 (Total Current Assets 583.3m / Total Current Liabilities 455.9m)
Debt / Equity = 0.36 (Debt 112.4m / totalStockholderEquity, last quarter 314.8m)
Debt / EBITDA = -0.74 (Net Debt -216.4m / EBITDA 292.2m)
Debt / FCF = -0.65 (Net Debt -216.4m / FCF TTM 333.2m)
Total Stockholder Equity = 287.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 27.55% (Net Income 219.9m / Total Assets 839.4m)
RoE = 76.65% (Net Income TTM 219.9m / Total Stockholder Equity 287.0m)
RoCE = 74.55% (EBIT 285.9m / Capital Employed (Total Assets 839.4m - Current Liab 455.9m))
RoIC = 78.14% (NOPAT 217.0m / Invested Capital 277.7m)
WACC = 10.59% (E(9.08b)/V(9.19b) * Re(10.72%) + D(112.4m)/V(9.19b) * Rd(0.59%) * (1-Tc(0.24)))
Discount Rate = 10.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.54%
[DCF Debug] Terminal Value 72.72% ; FCFF base≈308.4m ; Y1≈368.3m ; Y5≈582.0m
Fair Price DCF = 111.7 (EV 6.47b - Net Debt -216.4m = Equity 6.69b / Shares 59.8m; r=10.59% [WACC]; 5y FCF grow 20.73% → 2.90% )
EPS Correlation: 93.49 | EPS CAGR: 20.57% | SUE: 1.46 | # QB: 17
Revenue Correlation: 94.05 | Revenue CAGR: 11.63% | SUE: 1.43 | # QB: 4
EPS next Quarter (2026-03-31): EPS=1.12 | Chg30d=-0.126 | Revisions Net=-9 | Analysts=11
EPS current Year (2026-12-31): EPS=5.22 | Chg30d=-0.147 | Revisions Net=-5 | Growth EPS=+3.1% | Growth Revenue=+5.9%
EPS next Year (2027-12-31): EPS=5.86 | Chg30d=-0.086 | Revisions Net=-3 | Growth EPS=+12.2% | Growth Revenue=+8.8%